Post-RAMPART Implementation of Midazolam in EMS (PRIME) A retrospective, observational study of the use of IM midazolam.

Slides:



Advertisements
Similar presentations
Investigator Responsibilities in Clinical Research
Advertisements

Tips to a Successful Monitoring Visit
Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
What is a Data and Safety Monitoring Plan and how do I get one? Presented by Office of Human Research Protection.
University Research Ethics Committee Workshop on procedure and data protection issues 30th May 2008.
1 The HIPAA Privacy Rule and Research This presentation will probably involve audience discussion, which will create action items. Use PowerPoint to keep.
HIPAA – Privacy Rule and Research USCRF Research Educational Series March 19, 2003.
RESEARCH COMPLIANCE Agenda 1. No Destruction of local research documents after scanning 2. Training for shipping biological samples/specimens 3. Regulatory.
Protecting the Privacy of Family Members in Survey and Pedigree Research Jeffrey R. Botkin, MD, MPH University of Utah.
Health Insurance Portability Accountability Act of 1996 HIPAA for Researchers: IRB Related Issues HSC USC IRB.
Implementation of Privacy Board Reviews at PCMC Mary Thomason, Intermountain Healthcare Privacy Board Chair.
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
Pediatric Ethics Subcommittee of Pediatric Advisory Committee, September 10, 2004 Analysis of Research Protocols Involving Children: Combining Subparts.
IRB 101: Informed Consent Columbia University Medical Center IRB September 22, 2005.
IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.
Neurological Emergencies Treatment Trials Network RAMPART Overview Robert Silbergleit.
8 Criteria for IRB Approval of Research 45 CFR (a)
Pediatric Prehospital Seizure Management: Evidence Based Guidelines and State of Care in CO Kathleen Adelgais, MD MPH Pediatric Emergency Medicine Children’s.
Human Investigation Committee  Is it research?  If yes, does it involve human subjects?  If yes, can it be exempt?  If no, will a Request for.
Clinical Pharmacy’s Role in Research Trials Sheree Miller Pharm.D. Investigational Drug Service University of Washington Medical Center.
Health Insurance Portability and Accountability Act (HIPAA)
Is this Research? Exempt? Expedited?
Accredited Member of the Association of Clinical Research Professionals, USA Tips on clinical trials Maha Al-Farhan B.Sc, M.Phil., M.B.A., D.I.C.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Paula Peyrani, MD Medical/Project Director, HIV Program at the 550 Clinic Assistant Director, Research Design and Development Clinical and Translational.
International Research & Research Involving Children K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development.
Yesterday, today, and tomorrow
CHP400: Community Health Program - lI Mohamed M. B. Alnoor Research Methodology STUDY DESIGNS Observational / Analytical Studies Present: Disease Past:
Regulatory criteria for approval Bob Craig, July 2007.
Investigator Kickoff Meeting January Protocol Review, Part 1 Robert Silbergleit, MD.
Adverse Event/Unanticipated Problems Policy and Procedures November 2007.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
HIPAA – How Will the Regulations Impact Research?.
Human Research Protection Program 101 July 19-20, 2007 Milwaukee, WI.
Corticosteroid dosing in the treatment of acute exacerbations of COPD Kurt A. Wargo, Pharm.D., BCPS, Takova D. Wallace, Pharm.D. Candidate 2014, Ryan E.
CHP400: Community Health Program - lI Research Methodology STUDY DESIGNS Observational / Analytical Studies Present: Disease Past: Exposure Cross - section.
Building Clinical Infrastructure and Expert Support Michael Steinberg, MD, FACR ULAAC Disparity Project Centinela/Freeman Health System.
Professional Practices: Referral & Documentation Melody Kipp, PhD, LMHC Life & Work Soulutions, Inc.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Health Insurance portability and Accountability Act (HIPAA)‏
HIPAA and Human Subjects Research IRB Member CE May 2014 Slideshow by Sean Horkheimer.
Case Studies: Puzzles in Human Research Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst, Program for Research Integrity Development and Education.
Regulations 201: Thorny Issues What is Research? Exempt and Expedited Reviews.
WELCOME to the TULANE UNIVERSITY HUMAN RESEARCH PROTECTION OFFICE WORKSHOP for SOCIAL/BEHAVIORAL RESEARCH (March 2, 2010) Tulane University HRPO Uptown.
 Epidemiology -- Research – or Not Research? Medical Research Summit March Tom Puglisi, PhD.
1 The Impact of HIPAA on US Biomedical Research Presented To The: HIPAA SUMMIT Washington, DC March 28, 2003 Oliver Johnson, Chief Privacy Officer Merck.
Exempt Unless otherwise required by Department or Agency heads, research activities in which the only involvement of human subjects will be in one or more.
Human Research Protection Program 101 March 20, 2007 Cincinnati, OH.
Human Subjects Update E. Wethington, Chair, UCHS.
0 Ethics Lecture Research. ACADEMY OF OPHTHALMOLOGY Disclosures  The speaker has no financial interest in the subject matter of this.
PATIENT & FAMILY RIGHTS AT DOHMS. Fully understand and practice all your rights. You will receive a written copy of these rights from the Reception, Registration.
Research Documentation Betty Wilson, CIP, MS Senior Compliance Manager MU IRB Lori Wilcox, EdD Director of Academic Compliance, Corporate Compliance.
Informed Consent Presented by Marian Serge, RN. Goals Informed consent process and form Title 38 CFR , Common Rule required elements and additional.
Session 2 IRB Training  What is the Principal Investigator’s role in Human Subject Research?  What is the role of the Investigator’s staff in Human Subject.
Back to Basics – Approval Criteria
Clinicaltrials.gov Update
CLINICAL PROTOCOL DEVELOPMENT
What is a Data and Safety Monitoring Plan and how do I get one?
Jamie Reddish, MPH Research Compliance Administrator
Criteria for Approval Is an IND Required? Devices
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
The HIPAA Privacy Rule and Research
This takes approximately 5 minutes or less from start to finish
Exploring 45 CFR , Criteria for IRB Approval of Research
IRB Educational Session - IRB Regulations on Expedited Review
Research with Human Subjects
Presentation transcript:

Post-RAMPART Implementation of Midazolam in EMS (PRIME) A retrospective, observational study of the use of IM midazolam

Study Rationale There is a need to understand the process of implementation of clinical trial findings in the prehospital setting. In the absence of such understanding the use of effective prehospital treatments may be delayed, increasing morbidity. There is a need to understand the effectiveness of pre-hospital treatment of status epilepticus and to identify factors that predict treatment failure/success. Completion of the RAMPART trial provides a unique opportunity and environment to examine prehospital convulsive seizure therapy and changes in treatment.

Study Objectives 1. Evaluate prehospital use of midazolam for convulsive seizure before and after publication of the RAMPART trial results. 2. Explore effectiveness of post-RAMPART EMS drug therapies used in treating convulsive seizure/status epilepticus, specifically examining: Seizure cessation by emergency department arrival in patients receiving IM midazolam during the post-RAMPART period compared to historical controls from the RAMPART trial. Seizure cessation by emergency department arrival in post-RAMPART EMS-treated patients by drug and dose. Frequency and characteristics of pre-hospital treatment-resistant seizures (RAMPART treatment failures).

Hypotheses Objective 1: Publication of the RAMPART trial results did not influence IM midazolam use between the 12 months preceding publication and the post- publication follow-up period. Objective 2: IM midazolam administered according to local protocols following RAMPART trial completion was inferior to IM midazolam and IV lorazepam administered during the RAMPART trial in terminating convulsive seizure/status epilepticus prior to emergency department arrival.

Study Design Phase IV, retrospective, observational cohort study with descriptive and time-series analyses with RAMPART trial enrollees as historical controls as needed.

Subject Population EMS transported patients requiring treatment with benzodiazepines for convulsive seizure/status epilepticus in the prehospital setting. Adults Children with an estimated body weight of 13 kg or more

Inclusion Criteria EMS delivery of benzodiazepine Documentation of convulsive seizure activity either preceding or concurrent with benzodiazepine treatment Subject transported to a hospital where local study personnel have access to subject’s medical record

Exclusion Criteria Major trauma as the precipitant of the seizure Hypoglycemia (glucose < 60 mg/dl) Known allergy to benzodiazepines Cardiac arrest Bradycardia with a heart rate < 40 Treatment as part of another study Known pregnancy Prisoner

Primary Endpoint Objective 1: The primary outcome measure is the proportion of EMS transported patients treated with benzodiazepines for convulsive seizure who received intramuscular midazolam, evaluated monthly Objective 2: Termination of convulsive seizure activity prior to arrival in the emergency department after an initial prehospital dose of midazolam without the need for a second “rescue” dose of any benzodiazepine by EMS

Secondary Endpoints Treatment concordance with RAMPART clinical trial results. Treatment is considered concordant if 1) adults and those children with an estimated body weight of more than 40 kg received 10 mg of midazolam intramuscularly or 2) children with an estimated body weight of 13 kg to 40 kg received 5 mg of midazolam intramuscularly. Frequency of acute recurrence of seizure (either in EMS or ED) Frequency and duration of hospitalization Frequency and duration of ICU admission Frequency of acute endotracheal intubation Clinical, spatial and demographic characteristics of patients without termination of seizures prior to arrival in the ED and those with recurrent seizures in the prehospital or ED setting (treatment failures).

Treatments This is a retrospective, observational study. No subject treatments are planned

Data Collection Local study personnel will screen participating EMS systems for benzodiazepine use using available EMS logs and/or pharmacy data as appropriate for individual sites. Screen failures will be listed in the appropriate screen log form. Subjects meeting the inclusion and no exclusion criteria will undergo data collection using the EMS, Emergency Department and Inpatient medical record as required to complete data entry Copies or access to relevant primary source material from the medical record should be maintained in a secure manner for review on data monitoring visits.

Data Collection Schedule Data PrehospitalEmergency DepartmentHospital Discharge EMS Screen X Inclusion/Exclusion Criteria X Prehospital information X Demographic Data X History X Diagnostic Evaluation (first 6 hours) X Airway Intervention X Discharge Diagnosis X Discharge Data X

Study Periods The RAMPART trial ended in January EMS systems reverted to their standard protocols for the treatment of convulsive seizure following completion of the study. We estimate the study period will extend 27 months - from February 2011 to May This will cover three phases; 1. Pre-RAMPART result publication phase (Feb 2011 through Jan 2012) 2. Transition phase: the three months surrounding publication of the RAMPART results (Feb 2012 through April 2012) 3. Post-RAMPART result publication phase (May 2012 through April 2013) Final dates depend on the statistical analysis plan and budget

Statistical Analysis: Objective 1 Use of midazolam will be plotted graphically over time by one-month blocks from February 2011 through April Data from the three month transition period will be excluded from the statistical models but included in the visual presentation. We will assess change in the primary outcome before and after publication of the trial results. We will fit a time series linear regression to estimate monthly use of intravenous midazolam for convulsive seizure after publication of the RAMPART trial results. Details of the model and final analysis plan will be provided in the Statistical Analysis Plan (pending)

Ethics IRB review at each participating institution is required to demonstrate compliance with the conditions set out for the protection of human subjects as compiled in the “Common Rule”, 45 CFR 46 subparts A-D. Given the retrospective, observational nature of the study we plan to conduct it under a waiver of informed consent.

Waiver of informed consent The research involves no more than minimal risk to the subjects (i.e., the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests); The waiver or alteration will not adversely affect the rights and welfare of the subjects; The research could not practicably be carried out without the waiver or alteration; and Whenever appropriate, the subjects (including their physicians, as applicable) are provided with additional pertinent information after participation.

Confidentiality and Privacy An important objective of the PRIME study is to characterize treatment resistant seizures. It is therefore necessary to evaluate specific elements of protected health information. These include: subject age, treatment date and location, and hospital length of stay information, in order to identify characteristics associated with treatment failures.

HIPAA Waiver of Authorization HIPAA requires that the IRB or a Privacy Board find and document the following when a waiver of authorization will result in use or disclosure of protected health information (“PHI”) in connection with a research project: No more than a minimal risk to the privacy of individuals; Plan to protect the identifiers; Plan to destroy the identifiers; and Written assurances that the PHI will not be reused or disclosed to any other person or entity, except as required; The waiver will not adversely affect the privacy rights and the welfare of the individuals; The research could not practicably be conducted without the waiver; and The research could not practicably be conducted without use of the PHI

Quality Assurance The study will be conducted in accordance with the ICH Guidelines for Good Clinical Practice and all relevant local, national and international regulations. Hub investigators will provide quality assurance within their Hub spoke complex in a process called Verification. This is independent of Monitoring, which is used to mean only independent external monitoring by the NETT Project Monitor of the Clinical Coordinating Center. Data quality monitoring is performed continuously. Out of range and logical errors are identified at the time of data entry. Site visits may be conducted periodically by the Project Monitor(s). At site visits, the records of a sample of subjects will be reviewed against source documents. The proportion of records to be reviewed will be determined by the Statistical and Data Management Center.

Data Entry Form (draft) file://localhost/Users/phlsctt/Desktop/RAMPART Implementation Study/Reviewed Documents/PRIME Data Entry Form 1C DRAFT ps docx file://localhost/Users/phlsctt/Desktop/RAMPART Implementation Study/Reviewed Documents/PRIME Data Entry Form 1C DRAFT ps docx

Payment $1,500 start up payment for participating HUB/Spoke Complexes $160 / completed CRF, paid quarterly In RAMPART, each Hub/Spoke complex averaged 96 PRIME subjects per year Worth additional $15,360/year, on average, for each Hub/Spoke complex Large variation in screening between complexes, therefore reimbursement will have to be reviewed quarterly to ensure balance in enrollment and ability to complete needed duration of study for time series analysis

Questions?